July 26, 2017 1:13 AM ET

Healthcare Providers and Services

Company Overview of 21st Century Oncology, Inc.

Company Overview

21st Century Oncology, Inc. operates and manages radiation treatment centers primarily under the 21st Century Oncology name. Its centers provide radiation therapy and other integrated cancer care services to cancer patients. The company also has affiliations with physicians specializing in gynecological, breast and surgical oncology, medical oncology, urology, radiation oncology, general surgery, and primary care areas in various markets. It operates 181 treatment centers, including 145 centers in the 16 states of the United States; and 36 centers in 6 countries in Latin America. The company was formerly known as Radiation Therapy Services, Inc. and changed its name to 21st Century Oncology,...

2270 Colonial Boulevard

Fort Myers, FL 33907

United States

Founded in 1997

Phone:

239-931-7333

Key Executives for 21st Century Oncology, Inc.

Co-Founder and Director
Age: 71
CEO of Medical Developers Cooperatief UA BV and President of Medical Developers Cooperatief UA BV
Age: 57
Senior Vice President of Medical Affairs and Medical Director for Latin America
Age: 54
Chief Medical Officer
Age: 47
Senior Vice President of United States Operations
Age: 63
Compensation as of Fiscal Year 2017.

21st Century Oncology, Inc. Key Developments

Reorganization Plan Filed by 21st Century Oncology Holdings, Inc.

21st Century Oncology Holdings, Inc. filed a plan of reorganization in the US Bankruptcy Court on July 14, 2017. As per the plan filed, Administrative Claims, DIP Claims of $75 million, Professional Claims, Priority Tax Claims and Statutory Fees will be paid in full. Holders of Other Secured Claim will either be paid in full or be reinstated. Other Priority Claims will be paid in full in cash. MDL Claims of $35 million will pro rata share of loans provided under the New MDL Term Loan Facility of $10 million and payment in full in cash of the unpaid portion. First Lien Claims shall receive loans provided under the New First Lien Term Loan Credit Facility and cash. Note Claims shall receive New Notes Rights, New Preferred Equity Rights and share of the New Common Stock Equity Pool. if General Unsecured Claim is less than or equal to $1 million and such holder has not properly made the New Common Stock Election or is greater than $1 million and such holder has properly made the Convenience Claim Election then they will receive share of Convenience Claim Distribution of $0.50 million. If General Unsecured Claim is more than $1 million and such holder has not properly made the Convenience Claim Election or is less than or equal to $1 million and such holder has properly made the New Common Stock Election, then they will receive Pro Rata share of the New Common Stock Equity Pool. Intercompany Claims and Intercompany Interests shall be canceled or reinstated as of the Effective Date at the option of debtors. Holders of any Section 510(b) Claims shall not receive any recovery on account of such claims. All Interests in 21CH shall be canceled as of the Effective Date or reinstated at the Debtors’ option. In the event hat all Classes of Claims entitled to vote on the Plan vote to accept the Plan, there are no Allowed Section 510(b) Claims, and holders of Allowed Interests in 21CH and 21CI vote to accept the Plan, each holder of an Allowed Interest in 21CH shall receive, on the Effective Date Pro Rata share of the New Warrants. The plan will be funded from cash in hand, New MDL Term Loan Facility of $10 million, New First Lien Term Loan Credit Facility, New Domestic Revolving Credit Facility of $50 million, New Second Lien Notes of $200 million, common stock and rights offerings.

Final DIP Financing Approved for 21st Century Oncology Holdings, Inc.

The US Bankruptcy Court gave an order to 21st Century Oncology Holdings, Inc. to obtain DIP financing on final basis on June 20, 2017. As per the order, the debtor has been authorized to obtain a credit facility in the amount of $75 million from certain pre-petition lenders with Morgan Stanley Senior Funding, Inc. acting as the administrative agent. Prior to the termination of the RSA, the DIP loan would carry an interest rate of ABR plus 6.5% p.a, with floor of 2% p.a. in the case of ABR Loans and LIBOR plus 7.50% p.a. with a LIBOR Floor of 1% p.a. in the case of Eurodollar Loans. Upon the termination of the RSA, the DIP loan would carry an interest rate of ABR plus 7.25% p.a., with floor of 2% p.a. in the case of ABR Loans and LIBOR plus 8.25% p.a. with a LIBOR Floor of 1% p.a. in the case of Eurodollar Loans. The DIP loan would carry an additional 2% p.a. interest in the event of default. As per the terms of the DIP agreement, the loan carries a commitment fee of 0.75% p.a. The DIP Lenders shall receive from the Borrower OID payment in the aggregate amount of 2.00% of the Total DIP Commitments in case of termination of RSA and 1% upon the termination of RSA. The DIP facility would mature either on the date that is 180 days after the Closing Date. The maturity date can be extended by additional 90 days subject to the terms and conditions of the DIP Credit Agreement. The DIP Facility will be used to provide working capital, pay certain fees and expenses and for general corporate purposes of the Debtors during the Chapter 11 Cases. Adequate protection would be provided to the DIP lenders in the form of super-priority administrative expense claims which is subject to a carve-out of $2.55 million towards unpaid professional fees and administrative expenses and first priority lien upon and security interest in the debtor’s collateral. Cahill Gordon & Reindel LLP, Stroock & Stroock & Lavan LLP and Milbank, Tweed, Hadley & Mccloy LLP acted as legal counsels to the administrative agent.

Interim DIP Financing Approved for 21st Century Oncology Holdings, Inc.

The US Bankruptcy Court gave an order to 21st Century Oncology Holdings, Inc. to obtain DIP financing on an interim basis on May 26, 2017. As per the order, the debtor has been authorized to obtain a credit facility in the amount of $25 million out of $75 million from certain pre-petition lenders with Morgan Stanley Senior Funding, Inc. acting as the administrative agent. Prior to the termination of the RSA, the DIP loan would carry an interest rate of ABR plus 6.5% p.a, with floor of 2% p.a. in the case of ABR Loans and LIBOR plus 7.50% p.a. with a LIBOR Floor of 1% p.a. in the case of Eurodollar Loans. Upon the termination of the RSA, the DIP loan would carry an interest rate of ABR plus 7.25% p.a., with floor of 2% p.a. in the case of ABR Loans and LIBOR plus 8.25% p.a. with a LIBOR Floor of 1% p.a. in the case of Eurodollar Loans. The DIP loan would carry an additional 2% p.a. interest in the event of default. As per the terms of the DIP agreement, the loan carries a commitment fee of 0.75% p.a. The DIP Lenders shall receive from the Borrower OID payment in the aggregate amount of 2.00% of the Total DIP Commitments in case of termination of RSA and 1% upon the termination of RSA. The DIP facility would mature either on the date that is 180 days after the Closing Date. The maturity date can be extended by additional 90 days subject to the terms and conditions of the DIP Credit Agreement. The DIP Facility will be used to provide working capital, pay certain fees and expenses and for general corporate purposes of the Debtors during the Chapter 11 Cases. Adequate protection would be provided to the DIP lenders in the form of super-priority administrative expense claims which is subject to a carve-out of $2.05 million towards unpaid professional fees and administrative expenses and first priority lien upon and security interest in the debtor’s collateral. The final hearing date has been scheduled for June 19, 2017. Cahill Gordon & Reindel LLP, Stroock & Stroock & Lavan LLP and Milbank, Tweed, Hadley & Mccloy LLP acted as legal counsels to the administrative agent.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1104 Welsh Road Operations LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 21st Century Oncology, Inc., please visit www.21co.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.